Page 2 of 4

Application No.: 10/663,872

AMENDMENT

Docket 00825Div.JAR

LISTING OF CLAIMS

The following list of claims will replace all prior versions and listings of claims in the application.

Claims 1- 100 (cancelled)

Claim 101 (previously presented) A kit for assessing the hemostatic potential of a test sample comprising:

a single formulation of reagent comprising:

a first component comprising a coagulation activator present at a concentration level in an effective amount to trigger a thrombin formation but not to result in a complete fibrin polymerization of said blood or plasma sample; and

a second component comprising thrombomodulin;

wherein said single formulation of reagent is able to differentiate hyper, normal and hypocoagulable plasmas.

Claim 102 (previously presented) A kit according to claim 101 wherein said coagulation activator comprises tissue factor present in an amount ranging from 3 to 10 picomolar and said thrombomodulin is present in a range of from 5 to 20 nanomolar.

Claim 103 (previously presented) A kit according to claim 102 further comprising phospholipid vesicles present in an amount ranging from 100 to 150 micromolar and a metal salt present in an amount ranging from 5 to 50 mM.

Claim 104 (previously presented) A kit according to claim 103 further comprising a buffer with direction to dilute the reagent component with the buffer in a ratio of 1:3. Claim 105 (currently amended) A kit according to claim 101wherein said <u>coagulation</u> factor tissue factor is recombinant tissue factor that is relipidated with phospholipids. Claim 106 (currently amended) A kit for use in drug discovery and drug discovery of a test sample comprising:

a single formulation of reagent comprising:

Page 3 of 4

Application No.: 10/663,872

AMENDMENT

Docket 00825Div.JAR

a coagulation activator present at a concentration level in an effective amount to trigger a thrombin formation but not to result in a complete fibrin polymerization of said sample comprising blood or plasma,

wherein said single formulation of reagent is able to assess both the anticoagulant and procoagulant potential of a blood sample from a patient treated with either an inhibitor of the tissue factor pathway, an inhibitor of thrombin generation, or an inhibitor of thrombin activity acitivity.

Claim 107 (previously presented) A kit according to claim 106 further comprising a second component comprising thrombomodulin.

Claim 108 (previously presented) A kit according to claim 106 further comprising a second component comprising phospholipids present at a concentration which is not rate limiting to the coagulation process and remains constant and independent of dilution.

Claim 109 (previously presented) A kit according to claim 108 wherein said reagent also includes thrombomodulin is present in a range of from 5 to 20 nanomolar.

Claim 110 (currently amended) A kit according to claim 109 wherein wherien said phospholipid is present in an amount ranging from 100 to 150 micromolar.